A COPD flare can last for weeks and increase the risk of death. Roflumilast ( Daliresp ) is a phosphodiesterse-4 inhibitor approved by the FDA for severe COPD patients to treat flares involving chronic bronchitis. Daliresp reduces lung inflammation, but is not a bronchodilator and will not treat an acute attack; bronchodilators should be used in combination. Daliresp comes as an oral 500 microgram oral tablet dosed once a day. In clinical trials, some common side effects with Daliresp were diarrhea, nausea, headache, but weight loss and behavioral changes have been seen, too.
Lactation studies have not been conducted with oral budesonide, including ENTOCORT EC, and no information is available on the effects of the drug on the breastfed infant or the effects of the drug on milk production. One published study reports that budesonide is present in human milk following maternal inhalation of budesonide [see Data]. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ENTOCORT EC and any potential adverse effects on the breastfed infant from ENTOCORT EC, or from the underlying maternal condition.